Form 4: BridgeBio Pharma Director Executes Pre-Arranged Stock Option Exercise and Share Sale

BridgeBio Pharma, Inc. Director Hannah Valantine exercised stock options and subsequently sold 4,292 shares of common stock on June 10, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Hannah Valantine, a Director of BridgeBio Pharma, Inc. (BBIO), completed a transaction on June 10, 2025, involving the company's common stock.
• She acquired 4,292 shares of common stock by exercising stock options at a price of $16.75 per share.
• Concurrently, she disposed of 4,292 shares of common stock through a sale at a price of $40 per share.
• Both the exercise and sale were conducted pursuant to a Rule 10b5-1 sales plan, which was adopted by Ms. Valantine on December 5, 2024.
• Following these transactions, Ms. Valantine directly holds 1,764 shares of common stock and indirectly holds 3,433 shares through her spouse.
• She also retains 34,334 stock options with an exercise price of $16.75, which vest in three annual installments starting June 22, 2023, and concluding on June 22, 2025, contingent on her continued service on the Issuer's Board of Directors.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale occurred, it was pre-planned under a 10b5-1 plan, which generally mitigates negative market interpretations. The transaction was profitable for the insider, but it does not directly reflect on the company's operational performance or future prospects.

Positives

• The sale price of $40 per share is significantly higher than the exercise price of $16.75, indicating a profitable transaction for the insider.
• The transaction was executed under a Rule 10b5-1 plan, which suggests a pre-planned and routine sale rather than a reaction to recent, non-public information, often viewed favorably by the market.

Negatives

• An insider selling shares, even under a pre-arranged plan, can sometimes be perceived negatively by some market participants as it reduces the insider's direct equity stake in the company.

Risks

• This Form 4 filing primarily details insider trading activity and does not disclose specific risks related to the company's operational performance, financial health, or strategic outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance, strategic initiatives, or financial outlook, as its sole purpose is to report changes in insider beneficial ownership.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.
• The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023, and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Industry Context

This filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends, competitive dynamics, or specific market conditions. It reflects an individual director's pre-planned equity management rather than a company-wide strategic move.

Comparison to Industry Standards

• As a standard Form 4 filing detailing an insider's pre-arranged stock option exercise and subsequent sale, there are no direct industry-specific financial or operational benchmarks for comparison. Such transactions are common across publicly traded companies when insiders manage their equity compensation and are typically executed under Rule 10b5-1 plans to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, could be perceived as a slight reduction in insider alignment, though this is a routine transaction for equity compensation management and does not directly impact the company's operations or financial health.

Next Steps

• Continued service of Hannah Valantine on the Board of Directors for the remaining stock options to vest until June 22, 2025.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1, Hannah Valantine, Director, Beneficial Ownership